Bejelentkezés Regisztrálj ingyen

NeuroVive Pharmaceutical AB Jövedelem

Mi az NeuroVive Pharmaceutical AB Jövedelem?

A Jövedelem az NeuroVive Pharmaceutical AB - -kr114.29

Mi a Jövedelem meghatározása?

A közös részvényesek számára rendelkezésre álló nettó jövedelem egyenlő a nettó jövedelemmel mínusz a kifizetett előnyben részesített osztalékokkal.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Jövedelem a Miscellaneous szektor a LSE-on cégekben a NeuroVive Pharmaceutical AB -hoz képest

Mit csinál NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

jövedelem -hoz hasonló cégek NeuroVive Pharmaceutical AB